Title of study
Case-Control Study on Tracking Nursing Home Patients with Dementia
Name of Principal Investigator - Title
Name of Principal Investigator - First name
Name of Principal Investigator - Last name
Address of institution -Institution
Address of institution - Street address
Hôpital La-Grave-Casselardit 170 Avenue de Casselardit
Address of institution - City
Address of institution - Postcode
Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?
Alzheimer's disease and other dementias|Neurodegenerative disease in general
Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)
To assess the prelevance of systematically tracking dementia cases in EHPADs (institutions for dependent elderly people) within multidisciplinary team meetings.
Q2b. What distinguishes this case-control study from other studies?
It is performed in nursing home with a large number of residents included. The organization of multidisciplinary team meetings for dementia between patients' physicians, coordinator doctor and experts of memory clinics
Q3a. i) Number of publications that involve use of your cohort to date
Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)
J Nutr Health Aging. 2013 Feb;17(2):137-41. Multidisciplinary team meetings (MDTM) in detection of Alzheimer's disease: data from the IDEM study.Rolland Y1, Tavassoli N, Gillette-Guyonnet S, Perrin A, Hermabessière S, Ousset PJ, Nourhashemi F, Cestac P, Vellas B; IDEM investigators. J Nutr Health Aging. 2013 Feb;17(2):137-4
Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available
Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study
New approach to take care of AD patient in NH
Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:
Q4a. Study criteria: what is the age range of participants at recruitment? To:
Q4b. Study criteria: what are the inclusion criteria?
Male or female, 60 years or over, Institutionalized since 30 days or more, Life expectancy > 1 year, Residents and their GP having received information about the study, Residents and their GP having expressed their agreement to participate in the study
Q4c. Study criteria: what are the exclusion criteria?
Diagnosed and documented dementia [identified as follows: Identified by the French Healthcare system as suffering from dementia (ALD 15), Benefiting from a specific care program or a specialized follow-up for dementia, Appropriate investigation for dementia diagnosis in medical records, Taking specific drugs for dementia (Cholinesterase inhibitors and/or Memantine)]; GIR = 1; Suffering from a disease jeopardize participation in the study
Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?
Q5b. What is the expected number of control participants?
Q6a. Please describe what measures are used to characterise participants
AGGIR, number of hospitalizations in two groups, MMSE in cases
Q6b. Are there additional measures for participants with the clinical disorder?
Clock-drawing test, Mini-Cog, five word test, Test of categorical verbal fluency, CAM, one leg balance test, NPI, Mini-GDS, QOL-AD, IADL
Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?
If YES please specify
primary end point: Hospitalization in emergency units
Q7. What is the study design?
Q8. Are your cases matched by
Q9a. Does your study includes a specialised subset of control participants?
Q9b. If your study includes a specialised subset of control participants please describe
Q10a. Is data collection for this study
Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?
Q11. Are data collected
Only through the study|Through links to medical records
Q12. Is there a system in place to enable re-contact with patients for future studies?
Q13a. Please give information on data stored in a database (1)
Data summarised in database
Q13a. Please give information on data stored in a database (2)
Q13a. Please give information on data stored in a database (3)
Database on spreadsheet (e.g. excel)
Q13a. Please give information on data stored in a database (4)
Q13a. Please give information on data stored in a database (5)
Please specify language used
Q13b. Please give information on how data is held as individual records
Q14a. Are data available to other groups?
Q14b. If data is available to other groups what is the access policy/mechanisms for access?
Apply to PI or co-ordinator at resource
Q15. What data sharing policy is specified as a condition of use?
Q16a. Are tissues/samples/DNA available to other groups?
Q16b i) If yes, please describe below
Q16b. ii) In what form are tissues/samples/DNA supplied?
Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?
Q17. Is information on biological characteristics available to other groups?
Types: Case Control Studies
Member States: France
Diseases: Alzheimer's disease & other dementias, Neurodegenerative disease in general
Database Categories: N/A
Database Tags: N/A
Export as PDF